AstraZeneca’s Imfinzi (durvalumab) has been approved for NHS use in England and Wales for adults with limited-stage small ...

The MHRA has approved vorasidenib (Voranigo) for patients aged 12 and above with grade 2 astrocytoma or oligodendroglioma ...

Arcinova, a Quotient Sciences company and UK-based contract research development and manufacturing organisation (CRDMO), has ...

SOM Biotech has received a positive opinion from the European Medicines Agency’s Committee for Orphan Medical Products for SOM3355, a candidate therapy for Huntington’s disease (HD). The molecule ...

Thierry Van Nieuwenhove, CEO at Quotient Sciences, said: “This is a pivotal moment for RNA drug development. The combined ...

Lundbeck has presented new clinical data on eptinezumab at the 2025 International Headache Congress in São Paulo, ...

Bluejay Therapeutics has enrolled the first patient in AZURE-2, a global phase 3 clinical trial evaluating brelovitug ...

Merck has announced positive phase 3 results for Capvaxive, its 21-valent pneumococcal conjugate vaccine, in children and ...

Eisai has presented new clinical data for its investigational orexin 2 receptor agonist E2086 at the World Sleep 2025 ...

lzeCure Pharma has presented new clinical data on its lead pain candidate ACD440 at the NeuPSIG 2025 international pain ...

By uniting FSP and FSO services within a single governance structure, blended models provide a platform for sponsors to ...

Dr Deepika Jalota, Chief Development Officer, said: “These phase 2 PYNNACLE interim trial data illustrate that rezatapopt, a ...